These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
256 related articles for article (PubMed ID: 33258448)
1. Glutamine metabolism modulates azole susceptibility in Dumoulin PC; Vollrath J; Tomko SS; Wang JX; Burleigh B Elife; 2020 Dec; 9():. PubMed ID: 33258448 [TBL] [Abstract][Full Text] [Related]
2. Mevinolin (lovastatin) potentiates the antiproliferative effects of ketoconazole and terbinafine against Trypanosoma (Schizotrypanum) cruzi: in vitro and in vivo studies. Urbina JA; Lazardi K; Marchan E; Visbal G; Aguirre T; Piras MM; Piras R; Maldonado RA; Payares G; de Souza W Antimicrob Agents Chemother; 1993 Mar; 37(3):580-91. PubMed ID: 8460926 [TBL] [Abstract][Full Text] [Related]
3. In vitro and in vivo studies of the antiparasitic activity of sterol 14α-demethylase (CYP51) inhibitor VNI against drug-resistant strains of Trypanosoma cruzi. Soeiro Mde N; de Souza EM; da Silva CF; Batista Dda G; Batista MM; Pavão BP; Araújo JS; Aiub CA; da Silva PB; Lionel J; Britto C; Kim K; Sulikowski G; Hargrove TY; Waterman MR; Lepesheva GI Antimicrob Agents Chemother; 2013 Sep; 57(9):4151-63. PubMed ID: 23774435 [TBL] [Abstract][Full Text] [Related]
4. Antiproliferative effects of delta 24(25) sterol methyl transferase inhibitors on Trypanosoma (Schizotrypanum) cruzi: in vitro and in vivo studies. Urbina JA; Vivas J; Lazardi K; Molina J; Payares G; Piras MM; Piras R Chemotherapy; 1996; 42(4):294-307. PubMed ID: 8804798 [TBL] [Abstract][Full Text] [Related]
5. The activity of ketoconazole and other azoles against Trypanosoma cruzi: biochemistry and chemotherapeutic action in vitro. Goad LJ; Berens RL; Marr JJ; Beach DH; Holz GG Mol Biochem Parasitol; 1989 Jan; 32(2-3):179-89. PubMed ID: 2494453 [TBL] [Abstract][Full Text] [Related]
6. Antitrypanosomal Activity of Sterol 14α-Demethylase (CYP51) Inhibitors VNI and VFV in the Swiss Mouse Models of Chagas Disease Induced by the Trypanosoma cruzi Y Strain. Guedes-da-Silva FH; Batista DG; Da Silva CF; De Araújo JS; Pavão BP; Simões-Silva MR; Batista MM; Demarque KC; Moreira OC; Britto C; Lepesheva GI; Soeiro MN Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28167559 [TBL] [Abstract][Full Text] [Related]
9. Endogenous Sterol Synthesis Is Dispensable for Dumoulin PC; Vollrath J; Won MM; Wang JX; Burleigh BA Front Microbiol; 2022; 13():937910. PubMed ID: 35783434 [TBL] [Abstract][Full Text] [Related]
10. Clinical Candidate VT-1161's Antiparasitic Effect In Vitro, Activity in a Murine Model of Chagas Disease, and Structural Characterization in Complex with the Target Enzyme CYP51 from Trypanosoma cruzi. Hoekstra WJ; Hargrove TY; Wawrzak Z; da Gama Jaen Batista D; da Silva CF; Nefertiti AS; Rachakonda G; Schotzinger RJ; Villalta F; Soeiro Mde N; Lepesheva GI Antimicrob Agents Chemother; 2016 Feb; 60(2):1058-66. PubMed ID: 26643331 [TBL] [Abstract][Full Text] [Related]
12. Trypanosoma cruzi response to sterol biosynthesis inhibitors: morphophysiological alterations leading to cell death. Kessler RL; Soares MJ; Probst CM; Krieger MA PLoS One; 2013; 8(1):e55497. PubMed ID: 23383204 [TBL] [Abstract][Full Text] [Related]
13. Novel structural CYP51 mutation in Trypanosoma cruzi associated with multidrug resistance to CYP51 inhibitors and reduced infectivity. Franco CH; Warhurst DC; Bhattacharyya T; Au HYA; Le H; Giardini MA; Pascoalino BS; Torrecilhas AC; Romera LMD; Madeira RP; Schenkman S; Freitas-Junior LH; Chatelain E; Miles MA; Moraes CB Int J Parasitol Drugs Drug Resist; 2020 Aug; 13():107-120. PubMed ID: 32688218 [TBL] [Abstract][Full Text] [Related]
14. Nitroheterocyclic compounds are more efficacious than CYP51 inhibitors against Trypanosoma cruzi: implications for Chagas disease drug discovery and development. Moraes CB; Giardini MA; Kim H; Franco CH; Araujo-Junior AM; Schenkman S; Chatelain E; Freitas-Junior LH Sci Rep; 2014 Apr; 4():4703. PubMed ID: 24736467 [TBL] [Abstract][Full Text] [Related]
15. Complexes of Trypanosoma cruzi sterol 14α-demethylase (CYP51) with two pyridine-based drug candidates for Chagas disease: structural basis for pathogen selectivity. Hargrove TY; Wawrzak Z; Alexander PW; Chaplin JH; Keenan M; Charman SA; Perez CJ; Waterman MR; Chatelain E; Lepesheva GI J Biol Chem; 2013 Nov; 288(44):31602-15. PubMed ID: 24047900 [TBL] [Abstract][Full Text] [Related]
16. Antiproliferative effects and mechanism of action of ICI 195,739, a novel bis-triazole derivative, on epimastigotes and amastigotes of Trypanosoma (Schizotrypanum) cruzi. Urbina JA; Lazardi K; Aguirre T; Piras MM; Piras R Antimicrob Agents Chemother; 1991 Apr; 35(4):730-5. PubMed ID: 2069379 [TBL] [Abstract][Full Text] [Related]
17. Induction of resistance to azole drugs in Trypanosoma cruzi. Buckner FS; Wilson AJ; White TC; Van Voorhis WC Antimicrob Agents Chemother; 1998 Dec; 42(12):3245-50. PubMed ID: 9835521 [TBL] [Abstract][Full Text] [Related]
18. Listen to what the animals say: a systematic review and meta-analysis of sterol 14-demethylase inhibitor efficacy for in vivo models of Trypanosoma cruzi infection. Bisio MMC; Jurado Medina LS; García-Bournissen F; Gulin JEN Parasitol Res; 2024 Jun; 123(6):248. PubMed ID: 38904688 [TBL] [Abstract][Full Text] [Related]
19. A nonazole CYP51 inhibitor cures Chagas' disease in a mouse model of acute infection. Doyle PS; Chen CK; Johnston JB; Hopkins SD; Leung SS; Jacobson MP; Engel JC; McKerrow JH; Podust LM Antimicrob Agents Chemother; 2010 Jun; 54(6):2480-8. PubMed ID: 20385875 [TBL] [Abstract][Full Text] [Related]
20. Ultrastructural alterations induced by two ergosterol biosynthesis inhibitors, ketoconazole and terbinafine, on epimastigotes and amastigotes of Trypanosoma (Schizotrypanum) cruzi. Lazardi K; Urbina JA; de Souza W Antimicrob Agents Chemother; 1990 Nov; 34(11):2097-105. PubMed ID: 2073100 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]